骨硬化蛋白在肾性骨营养不良中的研究进展被引量：2

Research progress in sclerostin in the pathogenesis of renal osteodystrophy

下载PDF

导出

摘要肾性骨营养不良是慢性肾脏病(chronic kindey disease,CKD)患者常见且严重的并发症之一,将增加患者骨折风险和病残率,严重影响其生存质量。骨硬化蛋白(sclerostin)是一种由骨细胞表达的糖蛋白,其能够对骨骼生长代谢的各个阶段产生影响,并且参与了肾性骨营养不良的发病过程,本综述将对骨硬化蛋白在肾性骨营养不良中的研究进展进行探讨。 Renal osteodystrophy is one of the common and serious complications in CKD patients, leading to a significant increase in fracture risk and morbidity and seriously affecting the quality of life. Sclerostin is a glycoprotein expressed by bone cells, affects bone growth and metabolism at all stages, and participates in the pathogenesis of renal osteodystrophy. This review introduces the advances in the study of sclerostin in renal osteodystrophy.

作者董晶倩高山林 DONG Jing-qian;GAO Shan-lin(Graduate School of Hebei Medical University,Shijiazhuang 050000,China;Department of Nephrology,Tangshan Workers Hospital Affiliated to Hebei Medical University,Tangshan 063000,China)

机构地区河北医科大学研究生院河北医科大学附属唐山工人医院肾内科

出处《中国血液净化》 CSCD 2019年第11期766-768,共3页 Chinese Journal of Blood Purification

关键词慢性肾脏病肾性骨营养不良骨硬化蛋白 Chronic kidney disease Renal osteodystrophy Sclerostin

分类号 R692.5 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献2

1吴雪莹,张琢,徐天华,杜银科,王力宁,姚丽.维持性血液透析患者血清Sclerostin与血管钙化相关性分析[J].中国血液净化,2017,16(12):793-797. 被引量：15
2金是,颜佳毅,蔡宏,张伟明,陆任华,朱铭力,戚超君,方燕,谢园园,鲁嘉越,蒋蓉,邵兴华,王琴,周懿君,倪兆慧.维持性血液透析患者血清骨硬化蛋白水平与矿物质代谢及骨密度的相关性[J].中华肾脏病杂志,2015,31(10):729-735. 被引量：7

二级参考文献35

1生杰,赵久阳.慢性肾脏病患者的心血管钙化[J].中国血液净化,2012,11(1):49-50. 被引量：13
2Klawansky S, Komaroff E, Cavanaugh PF, Jr, et al. Relationship between age, renal function and bone mineral density in the US population[J]. Osteoporos Int, 2003, 14(7): 570-576.
3Yenchek RH, Ix JH, Shlipak MG, et al. Bone mineral density and fracture risk in older individuals with CKD[J]. Clin J Am Soc Nephrol, 2012, 7(7): 1130-1136.
4Taal MW, Roe S, Masud T, et al. Total hip bone mass predicts survival in chronic hemodialysis patients[J]. Kidney Int, 2003, 63(3): 1116-1120.
5Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength[J]. J Bone Miner Res, 2008, 23(6): 860-869.
6Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot - containing protein[J]. Am J Hum Genet, 2001, 68(3): 577 -589 .
7Zhu D, Mackenzie NC, Millan JL, et al. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells[J]. PLoS One, 2011, 6(5): e19595.
8Drechsler C, Evenepoel P, Vervloet MG, et al. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study[J]. Nephrol Dial Transplant, 2015, 30(2): 288 -293.
9Kauppila LI, Polak JF, Cupples LA, et al. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25 . year follow - up study[J]. Atherosclerosis, 1997, 132(2): 245-250.
10Wilson PW, Kauppila LI, O'Donnell CJ, et al. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality[J]. Circulation, 2001, 103(11): 1529- 1534.